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Early Prediction of Response to First-Line Therapy Using
Integrated 18F-FDG PET/CT for Patients with Advanced/
Metastatic Non-small Cell Lung Cancer
Dae Ho Lee, MD, Seok-Ki Kim, MD, Ho-Young Lee, MD, Sung Young Lee, MS, Sun Hwa Park, BS,
Hyae Young Kim, MD, Keon Wook Kang, MD, Ji-Youn Han, MD, Heung Tae Kim, MD,
and Jin Soo Lee, MD
Introduction: Early prediction of treatment response is of great
value to avoid unnecessary toxicity of ineffective treatment and to
get a chance to receive another effective treatment earlier. We
conducted a prospective study to evaluate the role of integrated
18-fluorodeoxyglucose positron emission tomography/computed to-
mography as a tool for early response predictor.
Methods: Between May 2004 and November 2005, 31 patients with
pathologically proven stage IIIB/IV non-small cell lung cancer
participated in this study. Metabolic response was assessed prospec-
tively after one cycle of systemic therapy, which was compared with
conventional radiographic response according to the World Health
Organization criteria.
Results: By the World Health Organization criteria, 10 of 31
patients (32.3%) achieved a partial response, 7 stable diseases, and
14 progressive diseases, whereas there were 7 partial metabolic
responses, 13 stable metabolic diseases, and 11 progressive meta-
bolic diseases. Out of 7 partial metabolic responses, 5 achieved
partial response, 1 stable disease, and 1 progressive disease (positive
predictive value of 71.4% [5 of 7]), whereas 9 of the 11 progressive
metabolic diseases had progressive diseases and the other 2 showed
stable diseases (negative predictive value of 100% [11 of 11]). There
were moderate correlation between early metabolic response and
best overall response (Spearman r  0.62, p  0.01). However, an
early metabolic response did not translate into better survival out-
come.
Conclusions: Single 18-fluorodeoxyglucose positron emission to-
mography/computed tomography scan taken after one cycle of
treatment could predict progressive disease earlier than standard
radiographic evaluation and can be used as a measure to avoid
ineffective systemic chemotherapy.
Key Words: Early response evaluation, 18F-FDG PET/CT, Non-
small cell lung cancer.
(J Thorac Oncol. 2009;4: 816–821)
Systemic chemotherapy, preferably with platinum-baseddoublets, remains the standard treatment for patients with
advanced or metastatic non-small cell lung cancer (NSCLC),
because it has been shown to prolong overall survival (OS)
and improve quality of life.1 However, overall response rates
were only about 40% with 1-year survival rate of 40%, and
majority of them experienced significant treatment-related
toxicity.2 To precisely and early predict tumor response is of
great value because we can avoid unnecessary toxicity and
additional cost of administering ineffective treatment, which
might increase the chance to receive other potentially effec-
tive treatments before further deterioration of performance
status. In addition, considering that many new drugs, espe-
cially molecular-targeted agents, were developed and intro-
duced in the treatment of NSCLC but most of them failed to
show the survival benefit in large clinical trials, early and
precise assessment of response of this new agent becomes
more important.
Positron emission tomography (PET) has been evalu-
ated as a method to predict tumor response in various tumor
types including NSCLC and its superiority to conventional
imaging was shown in several studies.3–7 Especially, when
using the response criteria recommended by the European
Organization for Research and Treatment of Cancer (EORTC),
a metabolic response was reported to correlate well with the
final outcome of therapy.8 In patients with locally advanced
NSCLC, metabolic response was reportedly superior to ra-
diologic response after completion of preoperative or defin-
itive chemoradiotherapy or radiotherapy.9,10 As recently in-
troduced, integrated PET and computed tomography (PET/
CT) scan provides the clearer anatomic information and
leads to precise localization of a lesion achieved on PET
within the anatomic reference frame obtained with CT, this
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is superior to either PET or CT alone or visual correlation
of PET with CT.11
Based on those findings, we conducted a pilot trial of
integrated 18-fluorodeoxyglucose (18F-FDG) PET/CT to
study prospectively whether metabolic response after one
cycle of treatment would correlate with radiologic response
and predict survival outcomes in patients with advanced or
metastatic NSCLC.
PATIENTS AND METHODS
Eligibility Criteria
The main eligibility criterion was pathologically con-
firmed stage IIIB NSCLC with pleural effusion or pericardial
effusion or stage IV NSCLC. However, bronchioloalveolar
carcinoma was excluded in this study because it might be
negative on a PET scan.12 Additional criteria were as follows:
(1) age of 18 to 75 years, (2) Eastern Cooperative Oncology
Group performance status of 0 or 1, (3) bidimensionally
measurable lesion(s) on CT scans, (4) adequate organ func-
tions (WBC 4.0  109/liter, neutrophils 2.0  109/liter,
platelets 100  109/liter, hemoglobin 10 mg/dl, alanine
aminotransferase or aspartate aminotransferase 2.5 times
the upper normal limit, serum bilirubin 1.2 mg/dl, and
serum creatinine 1.5 mg/dl), (5) no prior chemotherapy or
prior molecular-targeted therapy. The patients with symptom-
atic brain metastasis or uncontrolled diabetes mellitus, de-
fined as fasting blood glucose higher than 150 mg/dl, were
excluded. All patients signed a written informed consent
approved by the Institutional Review Board of National
Cancer Center. The study followed the Declaration of Hel-
sinki and Good Clinical Practice guidelines.
Treatment Plan
Eligible patients received standard chemotherapy or
molecular-targeted therapy until disease progression, unac-
ceptable toxicity, or patient’s withdrawal. Each cycle con-
sisted of 3 weeks of therapy and interruption of therapy was
allowed for a maximum of 2 weeks. Objective tumor re-
sponse was assessed prospectively according to the World
Health Organization (WHO) criteria after each cycle by chest
radiograph and every three cycles or every 9 weeks or when
clinically indicated by CT scans, and magnetic resonance
imaging where appropriate.13 All tumor responses were re-
viewed and confirmed by a referee radiologist (H.Y.K.) who
did not know results of PET/CT studies at all.
PET/CT images were obtained by using either one of
the two scanners, a Biograph LSO (Siemens Medical Solu-
tions, Hoffman Estates, IL) or a Discovery LS (General
Electric Medical Systems, Milwaukee, WI), but the same
scanner was allotted for follow-up evaluation of the same
patient. Two scannings were performed within 1 week before
and 3 weeks after treatment. Before obtaining a PET/CT
imaging, each patient had to fast for 8 hours or more, and then
received an intravenous injection of 444 to 740 MBq of
18F-FDG. PET/CT scanning was performed from the middle
of the skull to the upper thigh 60 minutes after the injection.
On each scanning, a spiral CT scan was performed using the
following parameters. For the Biograph LSO scanner, a scout
view at 30 mA and 130 kVp was followed by a spiral CT scan
with a 0.8-second rotation time, 50 mA, 130 kVp, 5-mm
section width, 4-mm collimation, and 12-mm table feed per
rotation with arms raised. For the Discovery LS scanner, a
scout view at 30 mA and 120 kVp was followed by a spiral
CT scan with a 0.8-second rotation time, 80 mA, 140 kVp,
5-mm section width, and 4.25-mm interval in high-speed
mode with arms at the sides of the torso. CT images were
reconstructed onto a 512  512 matrix and were converted
into 511 keV-equivalent attenuation factors for attenuation
correction. PET image acquisition followed CT scanning (3
minutes per bed position of 11.2 cm in three-dimensional
acquisition mode [Biograph LSO] or 4 minutes per bed
position of 14.2 cm in two-dimensional acquisition mode
[Discovery LS]) and PET images were reconstructed onto a
128  128 matrix using ordered-subsets expectation maxi-
mization and attenuation correction.
The images were analyzed using a dedicated worksta-
tion and eNtegra (General Electric Medical Systems) and
e-soft (Siemens Medical Solutions) software, which allowed
three-dimensional image display (transaxial, coronal, and
sagittal) and maximum intensity projection of PET data.
PET/CT images were interpreted by a consensus of at least
two of three nuclear medicine radiologists (H.Y.L., S.K.K.,
and K.W.K.) with 5, 9, and 10 years of experience, respec-
tively, who were unaware of any results from other imaging
studies. Nonenhanced CT scans from PET/CT were assessed
for the localization of the lesions and the differentiation of the
lesion from false positive lesions also. Volume of interest was
obtained for all focal hypermetabolic lesions, which were
detected visually, using a threshold of 50% according to the
pixel with local maximum FDG uptake. We could obtain
maximum standardized uptake value (SUVmax) and visible
tumor extent by measuring the longest dimension of volume
of interest. Inspired by the 1999 EORTC recommendations,8
in which partial metabolic response (PMR) would be classi-
fied as a reduction of a minimum of 15 to 25% in SUV after
one cycle of chemotherapy and progressive metabolic disease
(PMD) would be classified as an increase in SUV of greater
than 25% within the tumor region defined on the baseline
scan, we classified metabolic response as follows: PMD,
defined as an increase in SUVmax of greater than 25% within
the tumor region, visible increase in the extent of tumor
uptake (20% in the longest dimension), or the appearance
of new uptake in metastatic lesions in any tumor lesions;
stable metabolic disease (SMD), defined as an increase in
SUVmax of less than 25% or a decrease of less than 20% and
no visible increase in extent of tumor uptake (20% in the
longest dimension); PMR, defined as a reduction of a mini-
mum of 20% in SUVmax of all tumor lesions without visible
increase in extent of tumor uptake; and complete metabolic
response defined as complete resolution of uptake within the
tumor volume, which was indistinguishable from surrounding
normal tissue.
Statistical Analysis
This was a prospective observational single-center pilot
study. The parameters of interest are estimated and presented
with their 95% confidence intervals (CIs) using exact bino-
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mial probabilities. Analysis of variance was used to analyze
the change of SUVmax according to WHO response criteria.
Spearman’s or Pearson’s correlation coefficient was used to
describe the correlations. Progression-free survival (PFS) and
OS were defined as the interval between the date of the start
of treatment and the date of documented disease progression
or death from any cause, but PMD itself was not considered
as disease progression. If a patient was lost to follow-up, that
patient was censored at the last date of contact. All time-to-
event variables were estimated according to the Kaplan-
Meier method and compared by the log-rank test. Data were
updated as of February 4, 2009.
RESULTS
Patient’s Characteristics
Between May 2004 and November 2005, 31 patients
participated in this study and their characteristics are shown
in Table 1. Sixteen patients were treated with nonplatinum
doublets, 10 received cisplatin-based chemotherapy, and the
remaining five received gefitinib therapy.
Best Overall Response and Early Metabolic
Response
By the WHO criteria, 10 patients (32.3%, 95% CI;
16.7–51.4%) achieved a partial response (PR), including 2 of
the 5 patients treated with gefitinib, whereas there were 7
stable diseases (SD) and 14 progressive diseases (PD).
After one cycle of treatment, there were 7 PMRs, 13
SMDs, and 11 PMDs. Out of the seven PMR patients, five
achieved a PR whereas one had SD with minor tumor
shrinkage, and the other had PD due to a new small hepatic
nodule in his follow-up CT scan. Of the 11 PMD patients, 4
due to new hypermetabolic lesions and 7 due to an increase
in SUVmax of preexisting tumors, only 2 showed SD and the
remaining 9 had PD. Of the 13 SMD patients, 5 achieved PR
whereas 4 had SD and 4 had PD. The correlation between
early metabolic response and best overall response, as shown
in Table 2, was statistically significant (Spearman r  0.62;
95% CI, 0.34–0.81, p  0.01). None of the 11 PMD patients
achieved objective tumor response. With a receiver operating
characteristic area of 0.69, the positive and negative predict-
ability of PMR to predict a PR was 71.4% and 79.2%,
respectively, whereas with a receiver operating characteristic
area of 0.79, the corresponding values of PMD to predict
subsequent PD (9 of 11) was 75.0% and 81.8%, respectively.
When we evaluated PMR using different ranges for the
reduction in SUVmax values, that is a reduction of a minimum
of 15%, 25%, or 30%, there were still 7 PMRs and 13 SMDs
at 15%, while at 25% there were 4 PMRs and 16 SMDs, and
at 30%, there were 1 PMR and 19 SMDs.
Correlation of Variables Related to Metabolic
Changes After One Cycle of Treatment with
Objective Tumor Response
Percent change (% change) of SUVmax of a total of 295
individual lesions and its distribution, mean of the absolute
values of pretreatment and posttreatment SUVmax, and the
absolute value and its CIs of the mean of % change of
SUVmax are shown in Figure 1. The mean of % change of
SUVmax were 42.4% (95% CI, 50.0 to 34.7%) for PR,
25.3% (95% CI, 31.8 to 18.8%) for SD, and 8.1%
(95% CI,13.6 to2.7%) for PD, respectively, (p 0.001).
However, the % change of some lesions in one group over-
lapped with that in another group (Figure 1). We tried to
develop new metabolic responses according to the mean of %
change of hypermetabolic lesions as follows: new PMR,
decrease of 35% or more; new PMD, decrease of less than
15% or development of new lesions; and new SMD, neither
new PMR nor new PMD. As a result, out of 14 new PMDs,
TABLE 1. Baseline Patients’ Characteristics
Patients Characteristics Number %
Total 31 100
Age, median (range) 57 (30–73)
Gender
Male 23 74.2
Female 8 25.8
ECOG performance status
0 26 83.9
1 5 16.1
Histology
Adenocarcinoma 22 71.0
Squamous cell carcinoma 6 19.4
NSCLC, NOS 3 9.7
Stage
IIIB 2 6.5
IV 29 93.5
Evaluated lesions
Mean 9.8
Median (range) 6.5 (2–38)
Chemotherapy regimens
Gemcitabine/vinorelbine 16 51.6
Gemcitabine/vinorelbine/cisplatin 1 3.2
Gemcitabine/cisplatin 1 3.2
Irinotecan/cisplatin 8 25.8
Gefitinib 5 16.2
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer;
NOS, not otherwise specified.
TABLE 2. Correlation between Early Metabolic Response
Using 18F-FDG PET/CT and Subsequent Best Overall
Response According to WHO criteria
Metabolic Response
Best Overall Response
PR SD PD Total
PMR 5 1 1 7
SMD 5 4 4 13
PMD 0 2 9 11
Total 10 7 14 31
FDG, 18-fluorodeoxyglucose; PET, positron emission tomography; CT, computed
tomography; PR, partial response; SD, stable disease; PD, progressive disease; PMR,
progressive metabolic disease; SMD, stable metabolic disease; PMD, partial metabolic
response.
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there were 1 PR, 3 SD, and 10 PD, respectively, while out of
8 new PMRs, there were 5 PR, 1 SD, and 2 PD.
When changes of SUVmax of all 170 bidimensionally
measurable lesions on noncontrast CT scan of PET/CT scan
were assessed simultaneously, % change of SUVmax corre-
lated significantly but weakly with changes in the products of
bidimensional measurement (Pearson r  0.43; 95% CI,
0.30–0.54, p  0.01). However, the radiologic change of
lesions in nonenhanced CT scan could not give additional
information to increase the predictability of early metabolic
response, although noncontrast CT scan of PET/CT scan was
sometimes helpful to identify false positive inflammatory
lesions.
Survival Outcomes and Its Correlation with
Radiologic Response and Metabolic Response
After a median follow-up time of 42.9 months, two
patients are still alive while the others died of their cancer,
meaning that there was no expected difference between
deaths and cancer deaths in our study. The median PFS and
FIGURE 1. The change of maximum standardized uptake value (SUVmax) according to the World Health Organization
(WHO) response criteria. A, Percent change in hypermetabolic lesions and their means of according to their WHO response. B,
The value of SUVmax before and after one cycle. C, The means of percent change of SUVmax in tumors. PR, partial response;
SD, stable disease; PD, progressive disease.
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OS were 4.4 months (95% CI, 3.4–5.4) and 12.9 months
(95% CI, 9.9–15.8), respectively. Conventional radiologic
response significantly correlated to PFS (p  0.001) (Figure
2A) whereas early metabolic response might correlate mar-
ginally to PFS but not statistically significant (p  0.088)
(Figure 2C). Both did not predict survival time (p  0.089
and 0.342, respectively) (Figures 2B, D).
Subsequent Therapy After Failure of First-Line
Treatment
After failure of first-line treatment, 22 patients received
second-line therapy or more. The second-line treatment reg-
imens were as follows: gemcitabine/vinorelbine in five pa-
tients, irinotecan/cisplatin in five, gefitinib in five, paclitaxel/
carboplatin in two, gemcitabine/vinorelbine/cisplatin in two,
irinotecan/capecitabine in two, and docetaxel/capecitabine in
one. All 10 patients received gefitinib as second-line or
third-line treatment.
DISCUSSION
Because not all patients respond to the therapy and they
experience unnecessary treatment-related toxicity, it is im-
portant to early identify nonresponders and responders. Ad-
ministering a tailored therapy according to the status of a set
of predictive markers would be an ideal situation. However,
it is not always the case. Alternative is to find a way to predict
tumor response earlier than the conventional wisdom of
evaluating the tumor response. Recently, interest was drawn
to the possibility of using early metabolic change in tumors,
including NSCLC, detected by PET scan as a predictor for
objective tumor response.3–7,14,15
In the current study, 5 of the 7 PMR patients or early
metabolic responders eventually achieved a PR, while none
of the 11 PMD patients achieved an objective tumor re-
sponse. Although there are some limitations drawing any
significant conclusion, it seems reasonable to state that PMD
patients hardly show objective tumor responses, suggesting
that we can identify early a subset of patients who would not
benefit from highly toxic agents and even a molecular-
targeted agent. Because of nature of observational study,
although metabolic response and radiologic response was
assessed prospectively, we did not change the treatment
according to metabolic response, suggesting that further stud-
ies comparing survival outcomes based on conventional ra-
diologic response with those based on metabolic response are
warranted.
On assumption that metabolic change might steadily
increase or decrease after treatment, we have used our own
criteria inspired by the EORTC recommendations comparing
the baseline scan with a single scan taken 3 weeks after
initiating treatment. Our own cutoff value seemed to be
reasonable considering the result of our analyses with differ-
ent values, and those of other studies.6,10 However, because
of the heterogeneity of treatments, whether this value at 3
week is optimal for each treatment, especially daily oral
epidermal growth factor receptor tyrosine kinase inhibitor
therapy, is questionable. Further studies regarding optimal
timing of PET/CT scanning for molecular-targeted therapy
are warranted. Additional parameter, such as tumor/muscle
ratio or net-flux constants,6 or an additional scan between the
two scans, such as 10 days or 14 days after initiating treat-
ment, might give more information but of limited practical
significance. New tracers reflecting tumor proliferation or
hypoxia may well by more useful for earlier and more precise
response assessment than FDG tracer alone.
However, the definition of metabolic response, 20%
reduction in the SUVmax value in all lesions in a patient,
might be problematic, because at least in one of the lesions in
a patient might show low FDG uptake compared with the
surrounding normal tissues, such as liver. Actually, in the current
study, more than nine lesions per patients were evaluated but
about 50% of the lesions analyzed had the SUVmax of less
than 5. They might cause not only mathematically problem
but also affect the reproducibility of the FDG signal. In
FIGURE 2. Survival outcomes according to the
World Health Organization (WHO) response crite-
ria (A, B) and the European Organization for Re-
search and Treatment of Cancer (EORTC) meta-
bolic response criteria (C, D). A, Progression-free
survival according to radiologic response. B, Over-
all survival according radiologic response. C, Pro-
gression-free survival according to metabolic re-
sponse. D, Overall survival according to metabolic
response. PR, partial response; PMR, partial meta-
bolic response; SD, stable disease; SMD, stable
metabolic disease; PD, progressive disease; PMD,
progressive metabolic disease.
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addition, radiologic response uses decrease of the sum of the
measurable lesions by more than 50%, meaning that not all
lesions need to decrease by more than 50%. This may have
confounded our analysis. Retrospectively, we have also lim-
ited the analysis to lesions with a baseline SUVmax of more
than 5, and reached the same result and conclusion to the
above (not shown data). Therefore, the cutoff value of each
lesion, which could determine whether the lesion is metabol-
ically measurable or not, might be helpful to overcome the
limitation related to low metabolic lesions. However, the
cutoff value of each lesion to define a ‘metabolically mea-
surable lesion’ and the threshold value to evaluate ‘metabolic
response’ should be reinforced by the exercise of setting
different threshold in further studies.
We also tried to use nonenhanced CT scan of PET/CT
scanners to enhance the predictability of metabolic response.
Although it sometimes helped to differentiate false-positive
lesions from tumors, it could not change the classification of
early metabolic response. Each radiologic change of the
tumors correlated weakly with early metabolic change but it
was not more apparent than metabolic change of the same
lesions. Early radiologic response and metabolic response of
some lesions showed the opposite direction, but it was not
helpful because these were seen both in patients with PD and
PR. We further evaluated whether metabolic response of the
primary tumor or the lesion of highest metabolic activity
could correlate with the overall response, but it was not the
case (not shown data). Besides, the higher metabolic activity
itself did not correlate with either response or survival out-
come at least when systemic treatment was given. The mean
of % change of SUVmax was statistically different according
to the response criteria, but it was not also helpful enough to
decide the cutoff value or to early predict response. Theoret-
ically, our study has a few inherent potential weak points. We
used two types of scanners for our study. Because the spatial
resolution and sensitivity were different with scanners, the
values of quantitation were likely to have more potential
variability. But it was impractical to use the same scanner for
all the patients. As we used relative change of FDG uptake,
the error did not seem to be great.
In conclusion, early single FDG PET/CT scan was
useful in identifying the patients who would have progressive
disease. However, considering the fact that many patients
showed equivocal metabolic response on early assessment,
further studies are needed to addressing not only the timing,
frequency, and interval of FDG PET/CT scans but also the
efficacy of PET scans using other possible radiopharmaceu-
ticals.
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